Clinical Trial Search

Primary: Change in Pulmonary Function, as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry — -0.04 Liter — p=0.2030

Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.033; 0.090 Liter — p=<0.001

Primary: Composite End Point of Acute Rejection, Graft Loss or Patient Death — 1; 1; 0; 0 participants

Primary: Pain Assessment in Advanced Dementia (PAINAD) — 2.20; 2.56 units on a scale

Primary: Apathy Evaluation Scale Score at 12 Weeks — 38.2; 43.6 units on a scale — p=<0.05

Primary: Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment — 27.4; 29.5; 36.3 percentage of participants — p=0.6853

Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants

Primary: Number of Subjects With Inhibitory Anti-C1-esterase-inhibitor Antibodies — 0 subjects

Primary: Changes of Homocysteine Level — -0.68; -1.35 µmol/L — p=0.05

Primary: Numeric Pain Rating Scale (NPRS) — 6.09; 6.27; 3.73; 3.82 units on a scale

Primary: Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit — 0.366; -0.734 mmHg (millimeter of mercury) — p=0.274

Primary: Neutrophil Redistribution Analysis on Day 4 (Neutrophil Nadir) — 26.7; 26.5; 30.8; 50.4 percentage of total body count

Primary: Numerical Rating Scale — 5; 3 scores on a scale

Primary: Endothelial Function — 9.4; 8.8 percentage of maximal vasodilation — p=0.616

Primary: Intestinal Calcium Absorption — 0.200; 0.217; 0.183; 0.206 Total Fractional Calcium Absorption